Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lifted by TD Asset Management Inc

TD Asset Management Inc grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 397,552 shares of the biopharmaceutical company’s stock after buying an additional 23,288 shares during the period. TD Asset Management Inc’s holdings in Regeneron Pharmaceuticals were worth $306,858,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of REGN. Vanguard Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after buying an additional 26,884 shares during the period. Dodge & Cox boosted its stake in Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after acquiring an additional 724,562 shares during the period. Franklin Resources Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 6.0% during the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock valued at $1,379,329,000 after purchasing an additional 139,647 shares during the last quarter. Capital World Investors grew its holdings in shares of Regeneron Pharmaceuticals by 1.6% during the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock valued at $1,123,609,000 after purchasing an additional 32,348 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Regeneron Pharmaceuticals by 38.0% during the third quarter. Invesco Ltd. now owns 1,484,473 shares of the biopharmaceutical company’s stock valued at $834,675,000 after purchasing an additional 408,649 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $618.95 on Thursday. The stock has a market capitalization of $65.44 billion, a P/E ratio of 15.08, a P/E/G ratio of 1.33 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The business’s fifty day moving average is $711.47 and its two-hundred day moving average is $743.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue was up 19.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.22 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be issued a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent research reports. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $875.00 to $855.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Finally, Guggenheim raised their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $792.65.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.